ClinicalTrials.gg
RecruitingNCT05055297Updated Apr 28, 2026

SELUTION4BTK Trial

An interventional study of SELUTION SLR™ DEB 014 and Plain (Uncoated) Balloon Angioplasty (PTA) in Peripheral Arterial Disease and Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities, sponsored by M.A. Med Alliance S.A.. Recruiting at 48 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by M.A. Med Alliance S.A. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
376
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 479 studies in Peripheral Arterial Disease with a site in United States — 82 open to participants now, 101 under way, 10 of them phase 3. Peripheral Arterial Disease · United States.

Planned enrollment
33rd of 373
376 · median 64
Started
2022
with 19 others
No phase
217 of 479
40 open now
Primary completion
2027-06
later than 49 of 100 live
Registered
370th of 479
by date

Among the 479 studies in Peripheral Arterial Disease with a site in United States, this one is the 33rd largest by planned enrollment of the 373 interventional ones that give a count, is one of 20 that started in 2022, is one of 217 with no phase, reaches primary completion later than 49 of the 100 other live ones, and was the 370th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

82 of the 479 studies in Peripheral Arterial Disease with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 479 studies in Peripheral Arterial Disease with a site in United States, or all of them as a file.
02

Study summary

This study aims to demonstrate superior efficacy and equivalent safety of the SELUTION SLR™ DEB 014 compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the BTK arteries in CLTI patients.

03

Conditions studied

  • Peripheral Arterial Disease
  • Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Clinical Inclusion Criteria:

  1. Subject age is ≥ 18 years or older depending on local regulations.
  2. Subject is ≥ 1 year.
  3. Subject has documented chronic limb-threatening ischemia in the target limb with Rutherford classification category 4 or 5 and symptoms of > 2 weeks duration.
  4. Subject is willing and able to provide written and comply with study procedures and required follow-up evaluations.
  5. Female subjects of must be non-breastfeeding and have a negative pregnancy test ≤ 7 days before the procedure.

Angiographic Inclusion Criteria:

Subjects must meet all the following criteria to be enrolled in the trial:

  1. Target lesion(s) must be de novo or non-stented restenotic lesion(s) located within the BTK arteries distal to the tibial plateau and above the tibiotalar joint line. BTK arteries include the P3 segment of the popliteal artery, the tibio-peroneal trunk, peroneal artery, anterior tibial artery, and posterior tibial artery.
  2. BTK Target lesions cannot be contiguous with inflow lesions and at least 3 cm of normal artery should extend beyond the tibial plateau to ensure there is no overlap.
  3. Target lesions must have a diameter stenosis of ≥ 70% (including total occlusions) by visual estimate and must be indicated for PTA treatment.
  4. Target vessel reference diameter(s) are ≥ 2mm and ≤ 4mm. Note: the SELUTION SLR 014 DEB and the control PTA balloon size cannot exceed 4.0 mm.
  5. Target lesions must be confined to a single target vessel. NOTE: Subjects with other non-target BTK lesions in separate non-target vessels may be enrolled, provided that the non-target lesions have been successfully treated (residual stenosis ≤ 30% with no distal embolization or flow limiting ≥ Grade C dissection). NOTE: Any adjunctive therapies are permitted for the treatment of non-target BTK lesions, but no DEB or DES may be used.
  6. Any target lesion must be ≥ 30 mm in length and the total combined length of all target lesions must be ≤ 140 mm (total treatment length ≤ 150 mm allowing for 5 mm proximal and distal shoulder treatment). Note: All target lesions and all inflow lesions must be treatable by one or more SELUTION SLR 014/018 DEB(s) such that the total planned per-subject drug dose (calculated by summing the drug dose of all individual planned balloon sizes) would be ≤ 7069 μg. Note: A total treated segment length of ≤ 150 mm for BTK and ≤ 200 mm for inflow segment is acceptable irrespective of DEB balloon diameter.
  7. The tibial and pedal runoff distal to the target lesions must be patent OR the target vessel(s) must reconstitute above the ankle or display normal terminal branching as follows:

    1. If the target vessel is the P3 segment, any 1 of the 3 distal arteries must show a patent (≤ 50% stenosis by visual estimate) outflow.
    2. If the target vessel is the peroneal artery, the artery must demonstrate normal terminal branching.
    3. If the target vessel is the anterior tibial (AT) or posterior tibial (PT) artery, the artery must reconstitute ≥ 1 cm above the tibiotalar joint to provide an intact runoff vessel (AT: dorsalis pedis; PT: plantar artery).
    4. If the target vessel is the tibio-peroneal trunk, outflow for either the peroneal OR the posterior tibial artery must be patent (≤ 50% stenosis by visual estimate).
  8. Subjects is free of significant inflow vessel disease or any inflow disease has been successfully treated (see angiographic inclusion # 9). Significant inflow disease is defined as ≥ 50% stenosis by visual estimate. Inflow vessels include the ipsilateral common iliac, external iliac, common femoral, profunda femoris, superficial femoral or popliteal artery proximal (≥ 3 cm) to the tibial plateau. Note: If access site doesn't permit angiographic imaging of the common iliac and common femoral artery (CFA), then non-invasive imaging (CTA or MRA) must be provided to exclude presence of significant inflow disease. If non-invasive imaging is not possible, a DUS of the CFA with a multiphasic wave form excluding significant disease AND a palpable ipsilateral femoral pulse must be documented.
  9. Subjects with significant inflow disease (≥ 50% stenosis by visual estimate) must have documented successful treatment before randomizing the subject. Successful treatment of inflow disease is defined as ≤ 30% final residual stenosis and no distal embolization or flow-limiting > Grade C dissection. Note: Treatment of the common femoral and profunda femoris is not permitted. Inflow vessel treatment can be performed with any commercially available non-DCB or non-DES device; if DCB treatment is required, SELUTION SLR 018 must be used.
  10. The BTK target lesion preparation must be documented to be successful by angiography (≤ 30% residual stenosis and no distal embolization or flow-limiting ≥ Grade C dissection) before randomization. Note: Lesion preparation can include atherectomy (rotational, orbital, directional or laser), cutting, scoring, contoured balloons or intravascular lithotripsy and PTA only.

Clinical Exclusion Criteria:

Subjects will be excluded if any of the following criteria apply:

  1. Subject has extensive tissue loss (Rutherford category 6) extending above the trans metatarsal level, salvageable only with complex foot reconstruction or non-traditional trans metatarsal amputations. This includes subjects with:

    1. Osteomyelitis involving proximal to the metatarsal head(s)
    2. Any heel wound or wound with calcaneal bone involvement

    d) Wounds that would require flap coverage or complex wound management for large soft tissue defect e) Full-thickness wounds on the dorsum of the foot with exposed tendon or bone

  2. Subject has chronic renal insufficiency (dialysis dependent, or [GFR] ≤ 30 ml/min/1.73 m2 within 30 days of index procedure) or has undergone renal transplantation.
  3. Subject has acute renal insufficiency confirmed by 50% increase of serum creatinine within 48 hours before procedure and/or decrease in urine output.
  4. Subject has acute limb ischemia with onset of index limb symptoms less than 2 weeks prior to index procedure.
  5. Subjects has wounds that are deemed to be neuropathic or non-ischemic in nature or any venous or mixed wounds.
  6. Subject has had prior major amputation of the ipsilateral extremity or planned major amputation of either leg.
  7. Target limb iliac or common femoral artery bypass within 6 weeks of index procedure.
  8. Prior (within 14 days) or planned (within 30 days) surgical or endovascular procedures. The following procedures are permitted:

    1. Target limb inflow treatment at the index procedure, provided it meets the criteria in Angiographic Inclusion Criteria #12
    2. Contralateral limb iliac artery treatment
    3. Diagnostic angiography
    4. Foot wound debridement
    5. Planned minor amputation of digit(s) at the phalangeal level
  9. Target lesion has undergone prior DCB within 1 year, or ANY prior DES or bare metal stent (BMS) treatment (no in-stent restenosis [ISR] treatment is permitted). Note: Prior stent is permitted if the target lesion is located ≥ 30 mm from the stent AND there is ≤ 30% in-stent diameter stenosis.
  10. Target lesion(s) requires treatment with alternative therapies such as thrombolysis, thrombus aspiration, stenting, cryoplasty, brachytherapy, or re-entry device. Note: The following adjunctive lesion preparation therapies are permitted: Atherectomy (rotational, orbital, directional or laser), cutting/scoring/contoured balloon, or intravascular lithotripsy.
  11. Target lesion requires treatment via pedal access or upper extremity access.
  12. Subject has undergone non-coronary artery treatment with any limus-based drug coated balloon (DCB) or DES or other device within 3 months prior to index procedure.
  13. Subject has known or allergy to Sirolimus or other pharmacologic agents required for the procedure (such as contrast agent, heparin, bivalirudin) that cannot be adequately pre-treated.
  14. Subject has to antiplatelet therapy.
  15. Subject has experienced disabling stroke or ST-segment elevation myocardial infarction (STEMI) within 3 months of index procedure.
  16. Subject has acute coronary syndrome. Stabilized Acute Coronary Syndrome (ACS) is permitted.
  17. Subject has non-atherosclerotic disease of the target vessel (including aneurysmal disease and vasculitis) or Buerger's disease.
  18. Subject has hypercoagulable state or disorder, or coagulopathy, including count ≤ 100,000 per microliter.
  19. Subject has systemic infection (White Blood Count [WBC] > 12,000 and febrile). [Note: Enrollment permitted after successful treatment of infection with resolution of leukocytosis and/or febrile state].
  20. Subject is known to be immune compromised (e.g., [HIV], Systemic Lupus Erythematosus [SLE]) or is receiving treatment with immune suppressive medications (NOTE: topical are permitted)
  21. Subject is receiving (or is scheduled to receive) cancer treatment with surgery or chemotherapy or radiation therapy or has . Note: local application of chemotherapeutic creams is allowed.
  22. Subject has (NYHA) class IV congestive heart failure.
  23. Subject is bedridden.
  24. Subject has a (BMI) \< 18.
  25. Subject is currently participating in another drug or device study that has not completed primary endpoint follow-up.
  26. Subject has other anatomic, medical, social, or psychological conditions that in the investigator's opinion could limit the patient's ability to participate in the clinical study and/or comply with the follow-up requirements.

Angiographic Exclusion Criteria:

Subjects will be excluded if any of the following criteria apply:

  1. Presence of a previously placed stent in the target vessel(s), UNLESS the target lesion is located ≥ 30 mm from the stent AND there is ≤ 30% in-stent diameter stenosis.
  2. There is significant (> 50% diameter stenosis) inflow disease in the common femoral and profunda femoris arteries (inflow treatment of the common femoral and profunda femoris is not permitted).
  3. The target lesion could not be successfully pre-dilated (residual stenosis > 30%, distal embolization, or flow-limiting ≥ Grade C dissection after pre-dilatation).
  4. Intra-arterial thrombus, thromboembolism or atheroembolism in the index limb noted on initial diagnostic angiography or following treatment of inflow disease or pre-treatment of target lesion.
  5. Subject requires treatment of the tibial arteries distal to the tibiotalar joint line, or treatment of the pedal arteries. Angioplasty at or below the tibiotalar joint is not permitted.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
376 participants (estimated)

Study arms

  • Experimental
    SELUTION SLR™ DEB 014

    Device: SELUTION SLR™ DEB 014

  • Active comparator
    Plain (Uncoated) Balloon Angioplasty (PTA)

    Device: Plain (Uncoated) Balloon Angioplasty (PTA)

Interventions

  • DeviceSELUTION SLR™ DEB 014

    a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia

  • DevicePlain (Uncoated) Balloon Angioplasty (PTA)

    a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia

06

What researchers measure

Primary outcomes

  1. Primary Efficacy Endpoint

    Hierarchical composite efficacy endpoint determined by pair-wise comparisons among all subjects (Win Ratio method) according to the following pre-specified hierarchy of adverse outcomes: * Major (above-the-ankle) amputation * CD-TLR * Target lesion occlusion by angiography (if angiography is not available, the decision will be made on a secondary modality, in order of preference: computed tomography angiogram \[CTA\], magnetic resonance angiography \[MRA\] or DUS) * Transverse View Area Loss (TVAL%) by angiography.

    Time frame: 6 months

  2. Primary Safety Endpoint

    Freedom from the composite of MALE and all-cause perioperative death (POD). MALE is defined as major (above-the-ankle) amputation or major reintervention (new bypass graft, jump/ interposition graft revision, thrombectomy/thrombolysis) of the index limb.

    Time frame: 30 days

Secondary outcomes

  1. Primary sustained clinical improvement

    A secondary efficacy endpoint defined as freedom from target limb major amputation and CD-TLR AND increase in Rutherford category from baseline.

    Time frame: 1, 6, 12, 24, and 36 months

  2. Secondary sustained clinical improvement

    A secondary efficacy endpoint defined as freedom from target limb major amputation AND increase in Rutherford category from baseline.

    Time frame: 1, 6, 12, 24, and 36 months

  3. Major amputation

    A secondary efficacy endpoint defined as above-the-ankle amputation of the target limb.

    Time frame: 1, 6, 12, 24, and 36 months

  4. Amputation-free survival

    A secondary efficacy endpoint defined as freedom from all-cause mortality and major amputation.

    Time frame: 1, 6, 12, 24, and 36 months

  5. Primary assisted patency

    A secondary efficacy endpoint defined as freedom from ACL adjudicated occlusion on angiography or, if angiography is not available, by CTA, MRA or Duplex ultrasound core laboratory (DCL) adjudicated duplex ultrasound, irrespective of interventions for stenoses. • Secondary patency, defined as freedom from permanent occlusion (occlusion at the last follow-up imaging) as determined by the ACL or DCL.

    Time frame: 1, 6, 12, 24, and 36 months

  6. Secondary patency

    A secondary efficacy endpoint defined as freedom from permanent occlusion (occlusion at the last follow-up imaging) as determined by the ACL or DCL.

    Time frame: 1, 6, 12, 24, and 36 months

  7. CD-TLR

    A secondary efficacy endpoint defined as re-intervention on target lesion(s) due to recurrent/persistent/worsening symptoms and the angiographic finding of ≥ 50% restenosis of target lesion by ACL measurement.

    Time frame: 1, 6, 12, 24, and 36 months

  8. Clinically driven (CD-TVR)

    A secondary efficacy endpoint defined as re-intervention on target vessel due to recurrent/persistent/worsening symptoms and the angiographic finding of ≥ 50% restenosis of target vessel by ACL measurement.

    Time frame: 1, 6, 12, 24, and 36 months

  9. Rutherford category

    A secondary efficacy endpoint defined as change in Rutherford category from baseline.

    Time frame: 1, 6, 12, 24, and 36 months

  10. ABI/TBI/Toe Pressure

    A secondary efficacy endpoint defined as change in ankle brachial index (ABI), toe brachial index (TBI), and toe pressures from baseline. • Change in Quality of Life (QOL) measures from baseline (EQ-5D and VascuQol instruments)

    Time frame: 1, 6, 12, 24, and 36 months

  11. Quality of Life (QOL) measures

    A secondary efficacy endpoint defined as change in Quality of Life (QOL) measures from baseline (EQ-5D and VascuQol instruments).

    Time frame: 1, 6, 12, 24, and 36 months

  12. MALE

    A secondary safety endpoint defined as the composite of major (above-the-ankle) amputation or major reintervention (new bypass graft, jump/ interposition graft revision, thrombectomy/thrombolysis) of the index limb.

    Time frame: 1, 6, 12, 24, and 36 months

  13. Major cardiovascular events

    A secondary safety endpoint defined as the composite of cardiovascular death, myocardial infarction (MI), and stroke. • All-cause mortality \[evaluated at discharge, 1, 6, and 12 months and 2-5 years\]

    Time frame: 1, 6, 12, 24, and 36 months

  14. All-cause mortality

    Time frame: 1, 6, 12, 24, and 36 months

  15. Device success

    A secondary performance endpoint defined as successful delivery, balloon inflation, deflation and retrieval of the intact investigational device.

    Time frame: Post-procedure

  16. Procedural (technical) success

    A secondary performance endpoint defined as device success and residual diameter stenosis ≤ 30% on completion angiography by core lab assessment.

    Time frame: Post-procedure

  17. Clinical success

    A secondary performance endpoint defined as procedural success without procedural complications (death, above-ankle target limb amputation, thrombosis of the target lesion or TLR) prior to discharge.

    Time frame: Evaluated at discharge defined as immediately prior to hospital discharge from the index procedure or within 7 days, whichever occurs first

  18. Secondary Angiographic Imaging Measures

    * Subsegmental analysis: proportion of segments with binary restenosis (DS \> 50%) * Subsegmental analysis: Mean LLL of all segments; mean %DS of all segments. * TVAL%

    Time frame: 6 months

  19. Wound healing

    A secondary wound measure defined as investigator reported status of each index wound in comparison to baseline. Descriptive categories to be captured on case report forms (CRFs): 1) Improved 2) Unchanged 3) Worse 4) Healed/Complete Closure. Note: New wounds (appearing at any time after index procedure) are identified and tracked in similar fashion as index wounds, adopting the initial evaluation \& images as "baseline" for future comparisons.

    Time frame: 1, 6, 12, 24, and 36 months

  20. Wound Ischemia, foot infection (WifI) Classification

    A secondary wound measure defined as investigator-reported granular descriptors of Wound, Ischemia, and Foot Infection.

    Time frame: 1, 6, 12, 24, and 36 months

07

Study locations

41 of 48 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Jun 2027, 60 months after the start.

Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 60 months is above that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2021
First posted
Sep 24, 2021
StartActual
May 19, 2022
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jul 30, 2032
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05055297
Lead sponsor
M.A. Med Alliance S.A.
Collaborators
NAMSA, Cordis US Corp.
Responsible party
Sponsor
First posted
Sep 24, 2021
Start date
May 19, 2022
Primary completion
Jun 1, 2027 (estimated)
Completion
Jul 30, 2032 (estimated)
Last update
Apr 28, 2026

Study contacts

Kara Piscani
Contact
kara.piscani@cordis.com
+14846805857
Tamarah Suys
Contact
tamarah.suys@cordis.com
+41788957756

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion